Abera starts toxicology studies for pneumococcus vaccine candidate and reach the next milestone towards clinic
Abera Bioscience AB (“Abera” or the “Company”) announces that the toxicological studies for the universal pneumococcus vaccine candidate, Ab-01.12, is initiated which is an important